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Abstract
Purposes : To retrospectively determine the factors influencing treatment decisions in older breast cancer patients at a single
center. Experimental design : 216 patients age E/75 seen in post-treatment follow-up between January, 1997 and June, 2000 were
identified in the Memorial Sloan/Kettering breast cancer database. Eligible patients were E/75 years old at diagnosis, had a
diagnosis of stage I, II, or III breast cancer, and received their follow-up care at Memorial Sloan Kettering Cancer Center. A
retrospective chart review was performed. Patients were stratified by: (1) prognostic factors (age (75/79 or E/80), Charlson
comorbidity score, tumor size, nodal status, stage, ER, PR, creatinine, albumin, hemoglobin, and liver function tests), (2) local
treatment (lumpectomy, axillary lymph node dissection (AxLND), radiation (XRT), modified radical mastectomy (MRM)) and (3)
systemic treatment (tamoxifen, chemotherapy). Combined local treatment was defined as (a) lumpectomy, AxLND, XRT or (b)
MRM, AxLND, XRT (if tumor E/5 cm or E/4/ lymph nodes). Results : 96 patients were eligible for this study: 46 patients (75/79
years); 50 patients (E/80 years). The majority of patients (74%) were treated with lumpectomy but those E/80 were less likely to
receive XRT (94% age 75/80; 45% age /80; PB/0.01). Patients E/80 were also less likely to receive AxLND (94% age 75/79; 62%
age E/80; PB/0.01). A logistic regression model identified two independent prognostic variables for not receiving combined local
treatment: increased age (PB/0.01) and increased comorbidity score (P/0.01). Increased age did not correlate with increased
comorbidity (P/0.48). 5.2% of patients received adjuvant chemotherapy (all age B/80). 83% of ER positive patients received
tamoxifen (89% age 75/79; 79% age /80). Conclusion : We hypothesize that both comorbidity and age play a significant role in
influencing treatment decisions in the older breast cancer patient but these two variables are not necessarily correlated. Prospective
studies are needed to determine the relative impact of these variables.
# 2002 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Age is the dominant risk factor for breast cancer [1].
The number of older cancer patients is rapidly increas-
ing as our population is aging. In 1900 there were 3.1
million people age 65 and older. Presently there are
approximately 33.2 million people age 65 and older.
This number is continuing to grow, so that in 2030, an
estimated 70.2 million people will be over the age of 65
[2]. Despite the large number of older cancer patients,
few clinical trials have focused on this patient popula-
tion. The under-representation of older patients is
particularly notable in breast cancer treatment trials.
In a study of 164 Southwest Oncology Group treatment
trials between 1993 and 1996, only 9% of patients
enrolled in breast cancer studies were 65 or older;
however, approximately half of all breast cancers occur
in this age group [3].
Previous studies describe a pattern of less aggressive
care in the older breast cancer patients: older women less
likely to receive breast conservation therapy, less likely
to receive radiation, and less likely to receive chemother-
apy. [4/13] It is unclear whether physicians made these
treatment decisions based on age alone, or whether
other factors play a role in decision-making. In this
study, we examined the treatment patterns of women
age E/75 with early stage breast cancer at a large single
institution cancer center. This age cut-off was chosen,
rather than the traditional age E/65, in order to gain
more information about treatment patterns in this older
age group, which has not been as widely studied. In
addition, treatment decisions in this age group are often
more complex secondary to competing comorbid med-
ical conditions. The goal of this study is to determine
local and systemic treatment patterns in women age E/
75 and to understand factors influencing these treatment
decisions. In addition, we sought to determine whether
there is a significant difference in treatment patterns in
patients age 75/79, in comparison to patients older than
age 80.
2. Methods
The Memorial Sloan-Kettering Breast Cancer Data-
base was searched to identify all patients age 75 and
older that were seen in post-treatment follow-up be-
tween January, 1997 and June, 2000. Inclusion criteria
were: (1) patients E/75 years old at diagnosis (2)
diagnosis of stage I, II, or III breast cancer and (3)
patients must have received their follow-up care at
Memorial Sloan-Kettering Cancer Center. Patients
with bilateral or recurrent breast cancer were excluded.
A retrospective chart review was performed to gather
the data.
The following data was gathered: age (75/79 or E/
80), other comorbid medical conditions, tumor size,
nodal status, stage, ER/PR, creatinine, albumin, hemo-
globin, and liver function tests, local treatment (lum-
pectomy or modified radical mastectomy (MRM),
axillary lymph node dissection (AxLND), and radiation
(XRT) and systemic treatment (tamoxifen or che-
motherapy). A separate category entitled ‘combined
local treatment’ was defined as (a) lumpectomy,
AxLND, and XRT or (b) MRM, AxLND, and XRT,
(if tumor E/5 cm or E/4/ lymph nodes).
The Charlson comorbidity score was used to assess
the impact of comorbid medical conditions. Charlson et
al. developed this scale in 1987, using data from patients
on an internal medicine inpatient service [16]. Patients
were analyzed with respect to 1-year mortality as a
function of other comorbid medical conditions. As a
result, a comorbidity scale was developed consisting of
19 items. The scale has been validated in numerous
studies including studies of breast cancer patients and
studies in the older patient [17].
Univariate association of the following factors with
local treatment (lumpectomy or MRM, AxLND, and
XRT) and systemic treatment (tamoxifen or chemother-
apy) patterns was performed: age (75/79 or E/80),
Table 1
No significant difference in patient tumor characteristics or laboratory
values by age
Variables Age 75/79 Age/80 P value
T stage
1 34 (74%) 28 (56%) 0.13
2 7 (16%) 18 (36%)
3 1 (2%) 2 (4%)
4 3 (7%) 2 (4%)
Biopsy only 1 (2%) 0 (0%)
N stage
0 33 (72%) 22 (44%) 0.22
1 10 (22%) 13 (26%)
Nx 3 (7%) 15 (30%)
ER
(/) 37 (80%) 47 (94%) 0.14
(/) 6 (13%) 2 (4%)
NA 3 (7%) 1 (2%)
PR
(/) 28 (61%) 36 (72%) 0.50
(/) 15 (33%) 13 (26%)
Nx 3 (7%) 1 (2%)
Laboratory values
Creatinine 1.0 (SD 0.24) 1.0 (SD 0.21)
Albumin 4.3 (SD 0.31) 4.3 (SD 0.28)
Hemoglobin 13.4 (SD 1.2) 13.5 (SD 1.1)
Liver function tests
Normal 43 (93%) 40 (80%) 0.36
Abnormal 1 (2%) 3 (6%)
NA 2 (4%) 7 (14%)
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Charlson comorbidity score, tumor size, nodal status,
stage, ER/PR, creatinine, albumin, hemoglobin, and
liver function tests. A x2-test or Fisher’s exact test was
used to describe the association of categorical factors to
treatment patterns. Continuous data were analyzed
using a t-test. The independent prognostic values of
these factors in determining treatment decisions were
evaluated using logistic regressions. In all analyses, a
two tailed P value B/0.05 was considered significant.
3. Results
A total of 216 patients age E/75 were identified in the
Memorial Sloan/Kettering follow-up breast cancer
database between January, 1997 and June, 2000. Of
these, 96 patients were eligible for study. The majority of
those who were ineligible had not received their follow-
up care at MSKCC. Patient characteristics are detailed
in Table 1. Patients were stratified into two age groups:
age 75/79 (range 75/79, mean age 76.9) and age E/80
(range 80/96, mean age 84.5). There was no significant
difference in tumor and nodal stage between the two
patient groups. Seventy-five percent of patients had
stage I or II breast cancer. There was no significant
difference in hormone receptor status between patients
age 75/79 and patient age E/80. Eighty-eight percent of
patients had tumors that were hormone receptor posi-
tive.
Baseline laboratory values including hemoglobin,
creatinine (as a measure of renal function), albumin
(as a measure of nutritional status), and liver function
tests were recorded. There was no significant difference
in laboratory values between the two groups. The mean
creatinine of patients in both groups was 1.0 (SD 0.24
for age 75/79 and SD 0.21 for age E/80). The mean
albumin of patients in both groups was 4.3 (SD 0.31 for
age 75/79 and SD 0.28 for age E/80). The mean
hemoglobin for patients age 75/79 was 13.4 (SD 1.2)
and for patient age E/80 was 13.5 (SD 1.1). Eighty-
seven percent of patients had normal liver function tests.
Patient comorbidity was measured by the Charlson
comorbidity score (Table 2). The majority of patients
had a comorbidity score of 0 or 1 (94% age 75/79; 92%
age E/80). There was no significant difference in
comorbidity score with age. Increased comorbidity score
did not correlate with increased age either as a
continuous variable or when stratified by age 75/79
vs. age E/80.
Surgical treatment patterns are detailed in Table 3.
Patients were stratified by whether they received lum-
pectomy or MRM and whether they received AxLND.
The majority of patients received a lumpectomy (74% of
both age groups). A significantly lower number of
patients age E/80 received AxLND (93% age 75/79
and 70% age E/80; PB/0.01). Of the patients who
received a lumpectomy, significantly fewer patients E/
age 80 received radiation therapy (94% age 75/79 and
45% age E/80; PB/0.01) and AxLND (94% age 75/70
and 62% age E/80; PB/0.01) (Table 4). There is no
significant association between comorbidity score and
whether AxLND was performed; however there are few
patients with comorbidity score /1. Patients with
increased comorbidity score were significantly less likely
to receive radiation (Table 5).
Table 2
Charlson comorbidity score does not increase with age
Charlson comorbidity Age 75/79 Age/80 P value
0 33/46 (72%) 32/50 (64%) 0.48
1 10/46 (22%) 14/50 (28%)
2 2/46 (4%) 2/50 (4%)
3 0/46 (0%) 2/50 (4%)
4 1/46 (2%) 0/50 (0%)
Table 3
Surgical treatment patterns by age
Variables Age 75/79 Age/80 P value
Local surgery
Lumpectomy 34 (74%) 37 (74%) 0.9
MRM 11 (24%) 13 (26%)
Biopsy 1 (2%) 0 (0%)
Axillary dissection
Yes 43 (93%) 35 (70%) 0.01
No 3 (7%) 15 (30%)
Patients age E/80 are less likely to receive axillary dissection.
Table 4
Treatment patterns among patients with lumpectomy
Variables Age 75/79 Age/80 P value
XRT 32/34 (94%) 14/31 (45%) PB/0.01
AxLND 32/34 (94%) 23/37 (62%) PB/0.01
Patients age E/80 are less likely to receive XRT or AxLND.
Table 5
Increased Charlson comorbidity score and decreased likelihood to
receive XRT
Comorbidity score Radiation Total
No Yes
0 9 38 47
1 6 6 12
2 1 2 3
3 2 2
4 1 1
Total 19 46 65
x2 P/ 0.02.
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Only 38% of patients age 80 and older received
combined local treatment (‘combined local treatment’
was defined as (a) lumpectomy, AxLND, and XRT or
(b) MRM, AxLND, and XRT, (if tumor E/5 cm or E/
4/ lymph nodes)) in comparison to 87% of patients age
75/79 (PB/0.01). This data illustrates that a significant
number of patients age 80 and older do not undergo
axillary dissection or receive radiation after lumpectomy
or after treatment of high risk tumors by mastectomy.
In order to determine why women over the age of 80
were not receiving combined local treatment, patients
were stratified by the following prognostic factors: age
(75/79 or E/80), Charlson comorbidity score, tumor
size, nodal status, stage, ER/PR, creatinine, albumin,
hemoglobin, and liver function tests (Table 6). Two
factors independently predicted for lack of complete
local treatment: age E/80 (PB/0.01; odds ratio 10) and
comorbidity (P/0.01; odds ratio 2.5).
Systemic treatment patterns were also determined.
Patients were stratified as to whether they received
chemotherapy or tamoxifen (Table 7). A minority of
patients age 75 and older received adjuvant chemother-
apy: 5% of patients received adjuvant chemotherapy, all
in the 75/79 age group (mean age 75.8). No patients
older than 80 received adjuvant chemotherapy. In
contrast, a majority of patients with hormone receptor
positive tumors received tamoxifen: 89% of patients age
75/79 and 79% of patients age E/80. There is a trend for
patients E/age 80 with ER positive tumors to receive
less tamoxifen but this was not statistically significant.
4. Conclusions
In this study, we examined the treatment patterns of
women E/age 75 with early stage breast cancer at a large
single cancer center. The goal of this study is to
determine local and systemic treatment patterns in
women with breast cancer E/age 75, to understand
factors influencing these treatment decisions, and to
determine if there is a difference in treatment patterns in
patients age 75/79 in comparison to patients age E/80.
In this study, there was a difference in treatment
patterns in women with breast cancer age 75/79 in
comparison to age E/80. Patients age E/80 were
significantly less likely to receive an AxLND and XRT
in comparison to patients age 75/79. There was no
significant association between comorbidity score and
whether AxLND was performed; however there were
few patients with Charlson comorbidity score /1.
Patients with increased comorbidity score were signifi-
cantly less likely to receive radiation. A study by the
Cancer and Leukemia Group B demonstrated the
importance of radiation in decreasing the risk of
locoregional recurrence in older women who underwent
a lumpectomy. In this study, women, age 70 and older,
with clinical stage I, estrogen receptor positive disease
were randomized to lumpectomy alone or lumpectomy
plus radiation. With a median follow-up of 24 months,
women receiving lumpectomy alone had an increase in
locoregional recurrence in comparison to those treated
with lumpectomy and radiation [19].
In this study, ten prognostic factors were examined to
determine which variables would independently predict
for patients to not receive combined local treatment
(defined as (a) lumpectomy, AxLND, and XRT or (b)
MRM, AxLND, and XRT, (if tumor E/5 cm or E/4/
lymph nodes)). We identified two independent prognos-
tic variables predicting which individuals would not
receive combined local treatment: age E/80 and comor-
bidity score E/1. Increased age was the strongest
predictor of lesser treatment. Interestingly, increasing
age did not correlate with increased Charlson comor-
bidity score and patients older than age 80 did not have
increased comorbidity in comparison to those younger
than age 80. This may be a reflection of a healthier older
patient population seen in this large single institution
cancer center.
There was no significant difference in likelihood of
receiving hormonal therapy. Among patients with
Table 6
Prognostic factors predict for lack of local treatment
Prognostic
factors
Univariate
(P value)
Multivariate
(P value)
Odds
ratio
Age/80 B/0.01 B/0.01 10
Comorbidity E/1 0.02 0.01 2.5
T 0.38 NS
N 0.03 NS
ER 0.71 NS
PR /0.9 NS
CR 0.02 NS
Albumin 0.45 NS
Hemoglobin 0.85 NS
LFT /0.9 NS
Stage 0.12 NS
Table 7
Systemic treatment by age
No Yes Total
Tamoxifen a
Age 75/79 4 (11%) 31 (89%) 35
Age E/80 9 (21%) 33 (79%) 42
Total 13 (17%) 64 (83%) 77
Chemotherapyb
Age 75/79 41 (89%) 5 (11%) 46
Age E/80 46 (100%) 0 (0%) 46
Total 87 (95%) 5 (5%) 92
a x2 P/0.24; Fisher’s exact test P/0.36.
b x2 P/0.02; Fisher’s exact test P/0.06.
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hormone receptor positive tumors, there was a trend for
patients age E/80 (89% age 75/79 vs. 79% age E/80) to
receive less tamoxifen but this was not statistically
significant. It therefore appears that for less toxic
therapies, such as hormonal treatment, older women
were almost as likely as younger women to be treated.
However, for treatments that carry greater risk and
toxicity, such as chemotherapy or AxLND, older
women were less likely to be so treated.
In this study, very few patients were treated with
chemotherapy. The benefit of adjuvant chemotherapy in
early stage breast cancer was assessed in the worldwide
overview, published by the Early Breast Cancer Tria-
list’s Collaborative Group in 1998. Prolonged multi-
agent chemotherapy, in women under the age of 50,
decreased the annual odds of relapse by 35% and
mortality by 27%. The benefits were smaller but still
significant for women older than age 50: decreased the
annual odds of relapse by 20% and mortality by 11%.
For women age 60/69 years, the proportional risk
reduction for recurrence and mortality were 18 and
8%, respectively. There were not enough women over
the age of 70 to allow for subset analysis of these
patients [14]. The etiology of the decreased benefit of
chemotherapy with increasing age is not known; how-
ever, one possible explanation is that older women have
a different tumor biology secondary to more hormone
receptor positive tumors. Another possible explanation
is that the older women represented in the meta-analysis
were referred for treatment on a clinical trial because
they had a more aggressive tumor histology. Lastly,
older patients may have been given decreased che-
motherapy dose intensity in comparison to younger
patients, accounting for the decreased benefit with age.
Given the decreased benefit of adjuvant chemother-
apy in the older population in comparison to the
younger population, the decision to give adjuvant
chemotherapy needs to be based on the individual
patient’s risk of relapse, absolute benefit from che-
motherapy, and comorbid conditions which might limit
the ability to tolerate chemotherapy [14]. Extermann et
al. examined the threshold 10 year risk of relapse from
breast cancer needed for adjuvant chemotherapy to
produce a 1% absolute decrease in relapse or mortality,
taking into account the patient’s other comorbid
medical conditions that may be a competing source of
mortality. This information is valuable in considering
the absolute benefit of adjuvant treatment for an
individual patient [18].
In making treatment decisions with an older patient,
it is important to consider that, there may be some
patients who are functionally much younger than their
chronologic age who may derive greater benefit from
this treatment than would be suggested based on
chronological age alone. In addition, previous studies
have suggested that less definitive therapy may be
associated with a poorer outcome, although the results
of these limited studies are inconsistent [10/12,15].
For therapies that carry a higher risk to benefit ratio,
prognostic variables may help to define appropriate
candidates for treatment. In this study, comorbidity and
age were independent prognostic factors predicting for
treatment decisions. Factors other than comorbidity,
such as functional status and cognition might also be
helpful in distinguishing two individuals of the same age.
Limitations of our study include its retrospective
design, modest number of patients, and inability to
determine whether the treatment decisions were second-
ary to patient preference verses physician recommenda-
tion. In addition, the data presented in this study was
derived from a large tertiary care cancer center on the
East Coast. Previous studies have noted substantial
variability in patterns of care based on geographic
variation, with a greater likelihood to receive breast
conservation in a large city or if treatment was received
in a cancer center [7]. The differential in treatment
patterns of older cancer patients may be even greater in
other geographic locations. This data suggests that we
need further research regarding the risk, benefits, and
determinants of treatment patterns in older patients,
with a particular focus on the impact of treatment
decisions in patients age E/80. Prospective studies are
underway to address these questions.
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